Biodegradable vascular scaffold ABSORB BVS-Scientific evidence and methods of implantation;Wyniki dotyczace skutecznosci i bezpieczenstwa implantacji bioresorbowalnego rusztowania naczyniowego ABSORB w badaniach klinicznych

Postepy w Kardiologii Interwencyjnej

Volumn 9, Issue 1, 2013, Pages

  Rzeszutko, Lukasz ^a   Depukat, Rafal ^a,b   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Biodegradable vascular scaffold; Percutaneous coronary intervention

Indexed keywords

BIODEGRADABLE VASCULAR SCAFFOLD; MACROGOL; POLYLACTIC ACID; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ARTICLE; BARE METAL STENT; CARDIOLOGIST; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; HUMAN; IMPLANTATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT;

EID: 84876250202     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2013.34026     Document Type: Article

References (20)

1. http://www.abbott.com/news-media/press-releases/2011Jan10.htm
2. Nishio S, Kosuga K, Igaki K, et al. Long-term (> 10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012; 125: 2343-2353.
3. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of bio-degradable poly-L-lactic acid coronary stents in humans. Circulation 2000; 102: 399-404.
4. Tamai H. Biodegradable stents, an update and work in progress. Presentation at TCT 2003.
5. Tamai H. Biodegradable stents, four-year follow-up. Presentation at TCT 2004.
6. Depukat R, Dudek D. Biodegradable stents-4th revolution of the interventional cardiology. Postep Kardiol Inter 2009; 5: 144-147.
7. Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical followup of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Eurointervention 2012; 7: 1060-1061.
8. Nieman K, Dudek D, Ormiston J, et al. ABSORB cohort a trial: five year clinical and MSCT results of the ABSORB bioresorbable everolimus eluting vascular scaffold. Circulation 2011; 124: A10570.
9. Serruys, PW, Ormiston JA, Onuma Y, et al. A bioabsorbable eve-rolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
10. García-García HM, Gonzalo N, Pawar R, et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 2009; 4: 443-448.
11. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122: 2301-2312.
12. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.
13. Erbel R, Di Mario C, Bartunek J, et al.; PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-1875.
14. Waksman R, Erbel R, Di Mario C, et al.; PROGRESS-AMS (Clinical Performance Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Early-and long-term intra-vascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2009; 2: 312-320.
15. Ghimire G, Spiro J, Kharbanda R, et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention 2009; 4: 481-484.
16. Farooq V, Gomez-Lara J, Brugaletta S, et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a substudy of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv 2012; 79: 880-888.
17. Diletti R, Onuma Y, Farooq V, et al. Six-month clinical outcome following the implantation ofthe bioresorbable everolimus eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol 2011; 58: 258-264.
18. Gomez-Lara J, Diletti R, Brugaletta S, et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimuseluting bioresorbable vascular scaffold as assessed by optical coherence tomography. EuroIntervention 2012; 8: 214-224.
19. Legutko J, Rzeszutko L, Partyka L, et al. Comparison of three-dimensional and two-dimensional quantitative coronary analysis measuring intracoronary lengths in patients undergoing diagnostic coronary angiography. Postep Kardiol Inter 2012; 8: 31-41.
20. http://www.abbott.com/news-media/press-releases/abbottannounces- international-launch-of-the-absorb-bioresorbablevascular-scaffold.htm